Human Binding Domains Reduce Neurotoxicity of Anti-CD19 CAR-T Cells

No authors listed

Comment

No authors listed. Cancer Discov. 2020 Mar.

. 2020 Mar;10(3):338.

doi: 10.1158/2159-8290.CD-RW2020-017. Epub 2020 Jan 31.

Abstract

Anti-CD19 CAR-T cells with human binding domains were safer in B-cell lymphoma in a phase I trial.

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.
Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, Roschewski M, Dean R, Cachau R, Youkharibache P, Patel R, Hansen B, Stroncek DF, Rosenberg SA, Gress RE, Kochenderfer JN. Brudno JN, et al. Nat Med. 2020 Feb;26(2):270-280. doi: 10.1038/s41591-019-0737-3. Epub 2020 Jan 20. Nat Med. 2020. PMID: 31959992 Free PMC article. Clinical Trial.